INDIVIDUAL DOSE ADAPTATION OF ANTICANCER DRUGS

被引:41
作者
DESOIZE, B [1 ]
ROBERT, J [1 ]
机构
[1] FDN BERGONIE,BIOCHIM LAB,F-33076 BORDEAUX,FRANCE
关键词
ANTICANCER DRUGS; DOSE ADJUSTMENT; NEW THERAPEUTIC STRATEGY; PHARMACOKINETIC; PHARMACOLOGY;
D O I
10.1016/0959-8049(94)90304-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The dose of anticancer drugs is currently adjusted to the patient body surface area, although patients have different abilities to clear anticancer drugs. The dose adjustment to physiological functions permits major toxic accidents to be avoided. The adjustment to tumour drug content is considered, but for ethical or technical reasons, it cannot be used routinely The best criterion for the dose adjustment seems to be drug plasma concentration. The relationship between plasma concentration and efficacy may not be excellent, since it depends on the presence of resistant cells and on the blood how through the tumour. A relationship between plasma concentration and/or the area under the curve (AUC) with toxicity has been reported with all major anticancer drugs. Different methods of dose adjustment to the drug plasma concentration are reported. In conclusion, dose adjustment to the drug plasma concentration or to the AUC can improve the chemotherapy efficacy, while reducing toxicity.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 130 条
  • [1] PHARMACOKINETICS AND PHARMACODYNAMICS OF LONG-TERM CONTINUOUS-INFUSION DOXORUBICIN
    ACKLAND, SP
    RATAIN, MJ
    VOGELZANG, NJ
    CHOI, KE
    RUANE, M
    SINKULE, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) : 340 - 347
  • [2] HUMAN-PLASMA PHARMACOKINETICS OF THIOTEPA FOLLOWING ADMINISTRATION OF HIGH-DOSE THIOTEPA AND CYCLOPHOSPHAMIDE
    ACKLAND, SP
    CHOI, KE
    RATAIN, MJ
    EGORIN, MJ
    WILLIAMS, SF
    SINKULE, JA
    BITRAN, JD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) : 1192 - 1196
  • [3] RENAL-FUNCTION IN THE ELIMINATION OF ORAL MELPHALAN IN PATIENTS WITH MULTIPLE-MYELOMA
    ADAIR, CG
    BRIDGES, JM
    DESAI, ZR
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (02) : 185 - 188
  • [4] AU JLS, 1982, CANCER RES, V42, P2930
  • [5] PLASMA HALF-LIFE OF CYTOSINE-ARABINOSIDE IN PATIENTS WITH LEUKEMIA - EFFECT OF URIDINE
    BAGULEY, BC
    FALKENHAUG, EM
    [J]. EUROPEAN JOURNAL OF CANCER, 1975, 11 (01) : 43 - 49
  • [6] BALDUCCI L, 1989, SEMIN ONCOL, V16, P76
  • [7] BECOUARN Y, 1992, CANCER CHEMOTHER PHA, V29, P159
  • [8] BENNETT CL, 1987, CANCER RES, V47, P1952
  • [9] BIELING P, 1991, P AN M AM SOC CLIN, V10, P308
  • [10] BORSI JD, 1987, CANCER CHEMOTH PHARM, V19, P261